Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30406139 | 0.87 | EGFR (0.54) | EGFRTDO2ARESR1PIK3CD | |
| SCHEMBL9968621 | 0.87 | EGFR (0.54) | EGFRTDO2ARESR1PIK3CD | |
| SCHEMBL19605137 | 0.84 | EGFR (0.49) | EGFRIMPDH2TDO2HDAC1HDAC6 | |
| SCHEMBL9971269 | 0.81 | EGFR (0.51) | EGFRIMPDH2TDO2HDAC1HDAC6 | |
| SCHEMBL12064494 | 0.81 | EGFR (0.55) | EGFRIMPDH2TDO2HDAC1HDAC6 | |
| SCHEMBL22768263 | 0.79 | MAOB (0.43) | ESR1 | |
| SCHEMBL7203850 | 0.77 | EGFR (0.55) | EGFRIMPDH2TDO2HDAC1HDAC6 | |
| SCHEMBL3971054 | 0.77 | EGFR (0.55) | EGFRIMPDH2TDO2HDAC1HDAC6 | |
| SCHEMBL3822753 | 0.77 | EGFR (0.55) | EGFRIMPDH2TDO2HDAC1HDAC6 | |
| SCHEMBL27906316 | 0.77 | EGFR (0.55) | EGFRIMPDH2TDO2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| US-20210163486-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2021-06-03 | — | — | US | disclosed |
| US-20200281202-A1 | NOVEL FUNGICIDAL HETEROCYCLIC COMPOUNDS | PI INDUSTRIES LTD. (IN) | 2020-09-10 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-9540380-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150191476-A1 | Imidazotriazinone Compounds | FORUM PHARMACEUTICALS INC. | 2015-07-09 | — | — | US | disclosed |
| US-20140330014-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | EGFR 1658/4885IMPDH2 3019/4885TDO2 3858/4885 |
| US-20140330014-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | EGFR 4771/4885IMPDH2 70/4885TDO2 2295/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | EGFR 1658/4885IMPDH2 3019/4885TDO2 3858/4885 |
| US-20210163486-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | EGFR 2946/4885IMPDH2 959/4885TDO2 3051/4885 |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | EGFR 657/4885IMPDH2 2673/4885TDO2 368/4885 |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | EGFR 4771/4885IMPDH2 70/4885TDO2 2295/4885 |
| US-20200281202-A1 | NOVEL FUNGICIDAL HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP51A1 | EGFR 4822/4885IMPDH2 1912/4885TDO2 964/4885 |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | EGFR 4724/4885IMPDH2 109/4885TDO2 2754/4885 |
| US-20150191476-A1 | Imidazotriazinone Compounds | PDE9A, PDE12, PDE4A | EGFR 4724/4885IMPDH2 109/4885TDO2 2754/4885 |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | EGFR 139/4885IMPDH2 450/4885TDO2 1783/4885 |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | EGFR 4771/4885IMPDH2 70/4885TDO2 2295/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | EGFR 1658/4885IMPDH2 3019/4885TDO2 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.